Chauffert B - Search Results

1

Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromes.

Solary E, Mannone L, Moreau D, Caillot D, Casasnovas RO, Guy H, Grandjean M, Wolf JE, André F, Fenaux P, Canal P, Chauffert B, Wotawa A, Bayssas M, Genne P. Solary E, et al. Among authors: chauffert b. Leukemia. 2000 Dec;14(12):2085-94. doi: 10.1038/sj.leu.2401945. Leukemia. 2000. PMID: 11187897 Clinical Trial.

2

Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia.

Solary E, Caillot D, Chauffert B, Casasnovas RO, Dumas M, Maynadie M, Guy H. Solary E, et al. Among authors: chauffert b. J Clin Oncol. 1992 Nov;10(11):1730-6. doi: 10.1200/JCO.1992.10.11.1730. J Clin Oncol. 1992. PMID: 1357108

3

P-glycoprotein expression and in vitro reversion of doxorubicin resistance by verapamil in clinical specimens from acute leukaemia and myeloma.

Solary E, Bidan JM, Calvo F, Chauffert B, Caillot D, Mugneret F, Gauville C, Tsuruo T, Carli PM, Guy H. Solary E, et al. Among authors: chauffert b. Leukemia. 1991 Jul;5(7):592-7. Leukemia. 1991. PMID: 1677057

4

Comparative effects of quinine and cinchonine in reversing multidrug resistance on human leukemic cell line K562/ADM.

Genne P, Duchamp O, Solary E, Pinard D, Belon JP, Dimanche-Boitrel MT, Chauffert B. Genne P, et al. Among authors: chauffert b. Leukemia. 1994 Jan;8(1):160-4. Leukemia. 1994. PMID: 8289482

5

Sufficient levels of quinine in the serum circumvent the multidrug resistance of the human leukemic cell line K562/ADM.

Solary E, Velay I, Chauffert B, Bidan JM, Caillot D, Dumas M, Guy H. Solary E, et al. Among authors: chauffert b. Cancer. 1991 Oct 15;68(8):1714-9. doi: 10.1002/1097-0142(19911015)68:8<1714::aid-cncr2820680811>3.0.co;2-2. Cancer. 1991. PMID: 1913513

6

Quinine circumvents the doxorubicin resistance of a multidrug resistant human leukemic cell-line, K562/DXR.

Solary E, Velay I, Chauffert B, Caillot D, Bidan JM, Dumas M, Casasnovas O, Guy H. Solary E, et al. Among authors: chauffert b. Nouv Rev Fr Hematol (1978). 1990;32(5):361-3. Nouv Rev Fr Hematol (1978). 1990. PMID: 2099412

7

Cinchonine per os: efficient circumvention of P-glycoprotein-mediated multidrug resistance.

Genne P, Duchamp O, Solary E, Magnette J, Belon JP, Chauffert B. Genne P, et al. Among authors: chauffert b. Anticancer Drug Des. 1995 Mar;10(2):103-18. Anticancer Drug Des. 1995. PMID: 7710633

8

Cinchonine, a potent efflux inhibitor to circumvent anthracycline resistance in vivo.

Genne P, Dimanche-Boitrel MT, Mauvernay RY, Gutierrez G, Duchamp O, Petit JM, Martin F, Chauffert B. Genne P, et al. Among authors: chauffert b. Cancer Res. 1992 May 15;52(10):2797-801. Cancer Res. 1992. PMID: 1581892

9

Potential usefulness of quinine to circumvent the anthracycline resistance in clinical practice.

Chauffert B, Pelletier H, Corda C, Solary E, Bedenne L, Caillot D, Martin F. Chauffert B, et al. Br J Cancer. 1990 Sep;62(3):395-7. doi: 10.1038/bjc.1990.305. Br J Cancer. 1990. PMID: 2206948 Free PMC article.

10

Serum concentrations of amiodarone required for an in vivo modulation of anthracycline resistance.

Genne P, Coudert B, Pelletier H, Girardot C, Martin F, Chauffert B. Genne P, et al. Among authors: chauffert b. Anticancer Res. 1989 Nov-Dec;9(6):1655-9. Anticancer Res. 1989. PMID: 2627117

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

249 results

Search Page

Filters